Accelerate Diagnostics, Inc. announced that it has entered into a securities purchase agreement to issue 33,332 units at a price of $1.5 per unit for the gross proceeds of $49,998 and 2,716,762 units at a price of $1.73 per unit for the gross proceeds of $4,699,998.26 for the total gross proceeds of $4,749,996 on January 25, 2024. The transaction will include participation from individual investors, Chief Executive Officer and Chief Financial Officer for $49,998 and returning investor, Jack W. Schuler Living Trust for $4,749,996. The transaction became effective as of May 20, 2024.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.9301 USD | -1.61% | +8.28% | -76.27% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-76.27% | 20.15M | |
+8.07% | 219B | |
+6.59% | 183B | |
+11.26% | 133B | |
+26.57% | 108B | |
+0.65% | 63.06B | |
+13.35% | 52.02B | |
-0.62% | 48.2B | |
-0.93% | 40.37B | |
+11.54% | 39.35B |
- Stock Market
- Equities
- AXDX Stock
- News Accelerate Diagnostics, Inc.
- Accelerate Diagnostics, Inc. announced that it expects to receive $4.749996 million in funding from Jack W. Schuler Living Trust